E Krykowski

803 total citations
38 papers, 583 citations indexed

About

E Krykowski is a scholar working on Genetics, Hematology and Oncology. According to data from OpenAlex, E Krykowski has authored 38 papers receiving a total of 583 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Genetics, 12 papers in Hematology and 11 papers in Oncology. Recurrent topics in E Krykowski's work include Chronic Lymphocytic Leukemia Research (16 papers), Lymphoma Diagnosis and Treatment (8 papers) and Immunodeficiency and Autoimmune Disorders (7 papers). E Krykowski is often cited by papers focused on Chronic Lymphocytic Leukemia Research (16 papers), Lymphoma Diagnosis and Treatment (8 papers) and Immunodeficiency and Autoimmune Disorders (7 papers). E Krykowski collaborates with scholars based in Poland, Slovakia and United Kingdom. E Krykowski's co-authors include Tadeusz Robak, Maria Błasińska-Morawiec, L Konopka, Andrzej Hellmann, H Urbańska-Ryś, Jerzy Z. Błoński, Barbara Zdziarska, S Kotlarek-Haus, Krzysztof Warzocha and S Maj and has published in prestigious journals such as Blood, European Journal of Cancer and British Journal of Dermatology.

In The Last Decade

E Krykowski

35 papers receiving 567 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
E Krykowski Poland 11 402 375 193 191 68 38 583
U. Winkler Germany 10 269 0.7× 308 0.8× 214 1.1× 364 1.9× 75 1.1× 12 785
Carol Burian United States 9 605 1.5× 418 1.1× 241 1.2× 303 1.6× 58 0.9× 16 799
Natali Pflug Germany 13 446 1.1× 375 1.0× 223 1.2× 217 1.1× 109 1.6× 27 681
Annunziata Manna Italy 10 98 0.2× 228 0.6× 174 0.9× 138 0.7× 139 2.0× 29 485
P Travade France 7 361 0.9× 246 0.7× 60 0.3× 230 1.2× 78 1.1× 20 439
Brigitte Dreyfus France 10 887 2.2× 705 1.9× 121 0.6× 398 2.1× 240 3.5× 37 1.1k
Jeffrey K. Davies United Kingdom 8 281 0.7× 154 0.4× 315 1.6× 432 2.3× 130 1.9× 9 715
G. Brittinger Germany 8 165 0.4× 311 0.8× 236 1.2× 161 0.8× 40 0.6× 26 540
R. D. Brunning United States 12 194 0.5× 151 0.4× 84 0.4× 229 1.2× 252 3.7× 16 625
Antonella Teramo Italy 16 282 0.7× 271 0.7× 144 0.7× 402 2.1× 77 1.1× 38 722

Countries citing papers authored by E Krykowski

Since Specialization
Citations

This map shows the geographic impact of E Krykowski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E Krykowski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E Krykowski more than expected).

Fields of papers citing papers by E Krykowski

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E Krykowski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E Krykowski. The network helps show where E Krykowski may publish in the future.

Co-authorship network of co-authors of E Krykowski

This figure shows the co-authorship network connecting the top 25 collaborators of E Krykowski. A scholar is included among the top collaborators of E Krykowski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E Krykowski. E Krykowski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Robak, Ewa, et al.. (2005). Merkel cell carcinoma in a patient with B-cell chronic lymphocytic leukemia treated with cladribine and rituximab. Leukemia & lymphoma. 46(6). 909–914. 27 indexed citations
2.
Marczak, Agnieszka, et al.. (2003). The interaction of daunorubicin and mitoxantrone with the red blood cells of acute myeloid leukemia patients.. PubMed. 8(4). 885–90. 9 indexed citations
3.
Juszczyński, Przemysław, et al.. (2002). Expression of the Multidrug Resistance-associated Protein (mrp ) Gene in Chronic Lymphocytic Leukemia. Leukemia & lymphoma. 43(1). 153–158. 10 indexed citations
4.
Robak, Ewa, Tadeusz Robak, Wojciech Biernat, Jacek Bartkowiak, & E Krykowski. (2002). Successful treatment of leukaemia cutis with cladribine in a patient with B-cell chronic lymphocytic leukaemia. British Journal of Dermatology. 147(4). 775–780. 10 indexed citations
5.
Robak, Tadeusz, H Urbańska-Ryś, E Krykowski, et al.. (2001). Plasmablastic lymphoma in a patient with chronic lymphocytic leukemia heavily pretreated with cladribine (2‐CdA): an unusual variant of Richter's syndrome. European Journal Of Haematology. 67(5-6). 322–327. 62 indexed citations
6.
Kiliańska, Zofia M., Anetta Ptasinska, Jerzy Z. Błoński, et al.. (1998). Immunospecific protein with mol.WT of 38-39 kDa from lymphocytic leukemic cells. Cellular & Molecular Biology Letters. 3(1).
7.
Smolewski, Piotr, et al.. (1998). Expression of proliferating cell nuclear antigen (PCNA) and p53, bcl-2 or C-erb B-2 proteins on Reed-Sternberg cells: prognostic significance in Hodgkin's disease.. PubMed. 45(3). 140–7. 24 indexed citations
8.
Błasińska-Morawiec, Maria, Tadeusz Robak, E Krykowski, A. Hellmann, & H Urbańska-Ryś. (1997). Hairy cell leukemia–variant treated with 2-Chlorodeoxyadenosine—a report of three cases. Leukemia & lymphoma. 25(3-4). 381–385. 27 indexed citations
9.
Robak, Tadeusz, Maria Błasińska-Morawiec, E Krykowski, et al.. (1997). 2‐Chlorodeoxyadenosine (cladribine)‐related eosinophilia in patients with lymphoproliferative diseases. European Journal Of Haematology. 59(4). 216–220. 13 indexed citations
10.
Robak, Tadeusz, Maria Błasińska-Morawiec, E Krykowski, Andrzej Hellmann, & L Konopka. (1997). Autoimmune haemolytic anaemia in patients with chronic lymphocytic eukaemia treated with 2‐chlorodeoxyadenosine (cladribine). European Journal Of Haematology. 58(2). 109–113. 40 indexed citations
11.
Robak, Tadeusz, Maria Błasińska-Morawiec, Jerzy Z. Błoński, et al.. (1997). The effect of 2-h infusion of 2-chlorodeoxyadenosine (cladribine) with prednisone in previously untreated B-cell chronic lymphocytic leukaemia. European Journal of Cancer. 33(14). 2347–2351. 13 indexed citations
12.
Robak, Tadeusz, Maria Błasińska-Morawiec, E Krykowski, et al.. (1996). 2-Chlorodeoxyadenosine (2-CdA) in 2-Hour Versus 24-Hour Intravenous Infusion in the Treatment of Patients with Hairy Cell Leukemia. Leukemia & lymphoma. 22(1-2). 107–111. 50 indexed citations
13.
Krykowski, E, Krzysztof Warzocha, & Tadeusz Robak. (1995). 2-Chlorodeoxyadenosine (2-CdA) in the treatment of patients with relapsed chronic lymphocytic leukemia.. PubMed. 43(5-6). 317–21. 3 indexed citations
14.
Robak, Tadeusz, E Krykowski, & Krzysztof Warzocha. (1994). Treatment of chemotherapy-induced or idiopathic bone marrow aplasia with granulocyte colony-stimulating factor (G-CSF).. PubMed. 42(5-6). 433–8.
15.
Błasińska-Morawiec, Maria, et al.. (1991). [Late results of the treatment of advanced Hodgkin's disease by the MOPP/COPP programs (chlormethine or cyclophosphamide, vincristine, procarbazine and prednisone)].. PubMed. 86(4). 274–80. 1 indexed citations
16.
Krykowski, E, et al.. (1987). Analysis of Prognostic Factors in Acute Leukemias in Adults. Hämatologie und Bluttransfusion. 30. 369–372. 4 indexed citations
17.
Woźniak, L, et al.. (1981). Observations on angioimmunoblastic lymphadenopathy.. PubMed. 22(1). 81–95. 2 indexed citations
18.
Wozniak, Laura J., et al.. (1978). [Case of chronic exacerbated generalized toxoplasmosis coexistent with autoimmunohemolytic anemia].. PubMed. 24(4). 441–9. 3 indexed citations
19.
Krykowski, E, et al.. (1975). [Preleukemic conditions presenting as failure of bone marrow tissue].. PubMed. 30(1). 23–5.
20.
Musiał, W, et al.. (1966). [Studies on anemia in pregnancy].. PubMed. 21(9). Suppl:88–90. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026